ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2015
Evolving resistance among Gram-positive pathogens.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 133 citations in OpenAlex.
- Staphylococcus capitis strain producing dual bacteriocins, capidermicin and micrococcin P1, shows broad-spectrum antimicrobial activity.Scientific reports · 2026Article
- A New Preview of Antibiotic-resistant Spectrum in Community-acquired Pneumonia: A Cross-Sectional Study from Iraq.The open respiratory medicine journal · 2026Article
- Gram-positive ESKAPE pathogens in Germany: A comprehensive analysis of occurrence and resistance development in animal, food, and environmental sources.One health (Amsterdam, Netherlands) · 2025Review
- Transition metal complexes: next-generation photosensitizers for combating Gram-positive bacteria.Future medicinal chemistry · 2025Review
- LC-MS/MS Method for Simultaneous Quantification of Three Oxazolidinone Antimicrobials in Human Plasma: Application to Therapeutic Drug Monitoring.Drug design, development and therapy · 2025Article
- Evaluation of Antibiotic Resistance Mechanisms in Gram-Positive Bacteria.Antibiotics (Basel, Switzerland) · 2024Review
- Review
- Investigation on the Synergy between Membrane Permeabilizing Amphiphilic α-Hydrazido Acids and Commonly Used Antibiotics against Drug-Resistant Bacteria.Molecules (Basel, Switzerland) · 2024Article
- Analysis of molecular epidemiological characteristics and antimicrobial susceptibility of vancomycin-resistant and linezolid-resistant Enterococcus in China.BMC medical genomics · 2024Article
- D-Glucose-Mediated Gold Nanoparticle Fabrication for Colorimetric Detection of Foodborne Pathogens.Biosensors · 2024Article
- Modeling of Effectiveness ofMolecules (Basel, Switzerland) · 2024Article
- Antibiotic Resistance to Molecules Commonly Prescribed for the Treatment of Antibiotic-Resistant Gram-Positive Pathogens: What Is Relevant for the Clinician?Pathogens (Basel, Switzerland) · 2024Review
- Unleashing nature's defense: potent antimicrobial power of plant extracts against oral pathogens and Streptococcus mutans biofilms.Frontiers in oral health · 2024Article
- Drug Repurposing: Research Progress of Niclosamide and Its Derivatives on Antibacterial Activity.Infection and drug resistance · 2024Review
- Antibiogram of Bacteria Isolated from Bloodstream Infection-Suspected Patients at the University of Gondar Comprehensive Specialized Hospital in Northwest Ethiopia: A Retrospective Study.International journal of microbiology · 2024Article
- Progressive Design of a Ranatuerin-2 Peptide fromAntibiotics (Basel, Switzerland) · 2023Article
- Top-Down Genomic Surveillance Approach To Investigate the Genomic Epidemiology and Antibiotic Resistance Patterns of Enterococcus faecium Detected in Cancer Patients in Arkansas.Microbiology spectrum · 2023Article
- IgY antibodies: The promising potential to overcome antibiotic resistance.Frontiers in immunology · 2023Review
- Synergistic Inhibition of MRSA by Chenodeoxycholic Acid and Carbapenem Antibiotics.Antibiotics (Basel, Switzerland) · 2022Article
- Screening of Spore-Forming Bacteria with Probiotic Potential in Pristine Algerian Caves.Microbiology spectrum · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Antimicrobial therapy is a key component of modern medical practice and a cornerstone for the development of complex clinical interventions in critically ill patients. Unfortunately, the increasing problem of antimicrobial resistance is now recognized as a major public health threat jeopardizing the care of thousands of patients worldwide. Gram-positive pathogens exhibit an immense genetic repertoire to adapt and develop resistance to virtually all antimicrobials clinically available. As more molecules become available to treat resistant gram-positive infections, resistance emerges as an evolutionary response. Thus, antimicrobial resistance has to be envisaged as an evolving phenomenon that demands constant surveillance and continuous efforts to identify emerging mechanisms of resistance to optimize the use of antibiotics and create strategies to circumvent this problem. Here, we will provide a broad perspective on the clinical aspects of antibiotic resistance in relevant gram-positive pathogens with emphasis on the mechanistic strategies used by these organisms to avoid being killed by commonly used antimicrobial agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.